Comparative Pharmacology
Head-to-head clinical analysis: FAYOSIM versus PHENETRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAYOSIM versus PHENETRON.
FAYOSIM vs PHENETRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FAYOSIM (plecanatide) is a guanylate cyclase-C (GC-C) agonist. It binds to GC-C receptors on the luminal surface of intestinal epithelial cells, activating the receptor and increasing intracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP stimulates chloride and bicarbonate secretion into the intestinal lumen, enhancing fluid secretion and accelerating gastrointestinal transit, thereby promoting bowel movements.
Phenetron is an antihistamine that competes with histamine for H1-receptor sites, blocking histamine-mediated effects in the respiratory tract, vascular system, and gastrointestinal tract. It also exhibits anticholinergic and sedative properties.
10 mg orally once daily
Adults: 50 mg intramuscularly every 6 hours as needed.
None Documented
None Documented
12-16 hours in healthy adults; prolonged to 20-30 hours in moderate renal impairment (CrCl <50 mL/min) requiring dose adjustment.
Terminal half-life 12–15 hours; clinically, steady-state achieved in ~3 days
Primarily renal elimination, 80% unchanged drug in urine; 15% biliary/fecal; 5% metabolized.
Renal: ~70% unchanged; Biliary/Fecal: ~15% as metabolites; 15% unidentified
Category C
Category C
Antihistamine
Antihistamine